Biosimilar Guidance Puts BLA Sponsors On The Spot To Defend Reference Product Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance specifies what information a BLA sponsor must submit to show its product is entitled to period of exclusivity that limits FDA review or licensing of a biosimilar application.